Log in to save to my catalogue

Peptide-based LDH5 inhibitors enter cancer cells and impair proliferation

Peptide-based LDH5 inhibitors enter cancer cells and impair proliferation

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11802983

Peptide-based LDH5 inhibitors enter cancer cells and impair proliferation

About this item

Full title

Peptide-based LDH5 inhibitors enter cancer cells and impair proliferation

Publisher

Cham: Springer International Publishing

Journal title

Cellular and molecular life sciences : CMLS, 2022-12, Vol.79 (12), p.606-606, Article 606

Language

English

Formats

Publication information

Publisher

Cham: Springer International Publishing

More information

Scope and Contents

Contents

Lactate dehydrogenase 5 (LDH5) is overexpressed in many cancers and is a potential target for anticancer therapy due to its role in aerobic glycolysis. Small-molecule drugs have been developed as competitive inhibitors to bind substrate/cofactor sites of LDH5, but none reached the clinic to date. Recently, we designed the first LDH5 non-competitive...

Alternative Titles

Full title

Peptide-based LDH5 inhibitors enter cancer cells and impair proliferation

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11802983

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11802983

Other Identifiers

ISSN

1420-682X

E-ISSN

1420-9071

DOI

10.1007/s00018-022-04633-3

How to access this item